Uncategorized

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Intravacc, a leading Contract Development and Manufacturing Organization specializing in translational research and the development of preventive and therapeutic vaccines, has announced the publication of a review on the efficacy of intranasally administered outer membrane vesicle -based vaccines.

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention Read More »

InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

InnoCare Pharm announced the approval of the Investigational New Drug to conduct the clinical trial of ICP-189, a novel SHP2 allosteric inhibitor, in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in China.

InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib Read More »

BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

BIOLASE, Inc., a global leader in dental lasers, announced the pricing of an underwritten public offering of 75,000 units, with each Unit consisting of one share of BIOLASE’s Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share, and one warrant to purchase one-half of one

BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants Read More »

Scroll to Top